Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
New England Journal of Medicine, Volume 363, No. 27, Year 2010
Notification
URL copied to clipboard!
Description
Background Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. Methods We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections. Results The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P = 0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P = 0.57). Conclusions Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.). © 2010 Massachusetts Medical Society.
Authors & Co-Authors
Grant, Robert M.
United States, San Francisco
University of California, San Francisco
United States, San Francisco
Hiv Research Section
Lama, Javier R.
United States, Lima
Asoci-ación Civil Impacta Salud y Educaciön
Peru, Iquitos
Asociación Civil Selva Amazónica
United States, Foster City
Gilead Sciences Incorporated
Anderson, Peter L.
United States, Denver
University of Colorado Denver
McMahan, Vanessa M.
United States, San Francisco
University of California, San Francisco
Liu, Albert Y.
United States, San Francisco
Hiv Research Section
United States, Lima
Investigaciones Medicas en Salud
Vargas, Lorena
United States, San Francisco
University of California, San Francisco
Goicochea, Pedro
Unknown Affiliation
Casapia, Martin
Peru, Iquitos
Asociación Civil Selva Amazónica
Guanira, Juan Vicente
Peru, Iquitos
Asociación Civil Selva Amazónica
Ramirez-Cardich, Maria E.
Peru, Iquitos
Asociación Civil Selva Amazónica
Montoya-Herrera, Orlando
United States, Lima
Asoci-ación Civil Impacta Salud y Educaciön
Ecuador, Guayaquil
Fundacion Ecuatoriana Equidad
Fernández, Telmo
United States, Lima
Asoci-ación Civil Impacta Salud y Educaciön
Ecuador, Guayaquil
Fundacion Ecuatoriana Equidad
Veloso, V. G.
Brazil, Rio de Janeiro
Instituto Nacional de Infectologia Evandro Chagas Ini
Buchbinder, Susan P.
United States, San Francisco
Hiv Research Section
United States, Lima
Investigaciones Medicas en Salud
Chariyalertsak, Suwat
Thailand, Chaing Mai
Chiang Mai University
Chariyalertsak, Mauro Schechter
Brazil, Rio de Janeiro
Universidade Federal do Rio de Janeiro
Bekker, Linda-Gail Gail
South Africa, Cape Town
University of Cape Town
Mayer, Kenneth H.
United States, Providence
Brown University
United States, Boston
Fenway Community Health Center
Kállas, Èsper Georges
Brazil, Sao Paulo
Universidade de São Paulo
Brazil, Sao Paulo
Instituto de Investigação em Imunologia
Rivet Amico, K. Rivet
United States, Brighton
Applied Health Research
United States, Storrs
University of Connecticut
Mulligan, Kathleen
United States, San Francisco
Hiv Research Section
Bushma, Lane R.
United States, Denver
University of Colorado Denver
Hance, Robert J.
United States, San Francisco
University of California, San Francisco
Ganoza, Carmela
Peru, Iquitos
Asociación Civil Selva Amazónica
Defechereux, Patricia A.
United States, San Francisco
University of California, San Francisco
Postle, Brian
United States, Seattle
Df/net Research
Wang, Furong
United States, San Francisco
Hiv Research Section
McConnell, Jeff
United States, San Francisco
University of California, San Francisco
Zheng, Jia Hua
United States, Denver
University of Colorado Denver
Lee, Jeanny
United States, San Francisco
University of California, San Francisco
Rooney, James F.
Brazil, Sao Paulo
Universidade de São Paulo
Jaff, Howard S.
United States, Foster City
Gilead Sciences Incorporated
Martinez, Ana Isabel
United States, Bethesda
National Institute of Allergy and Infectious Diseases Niaid
Burns, David N.
United States, Bethesda
National Institute of Allergy and Infectious Diseases Niaid
Glidden, David V.
United States, San Francisco
Hiv Research Section
Statistics
Citations: 4,192
Authors: 35
Affiliations: 20
Identifiers
Doi:
10.1056/NEJMoa1011205
ISSN:
00284793
e-ISSN:
15334406
Research Areas
Health System And Policy
Infectious Diseases
Sexual And Reproductive Health
Study Design
Cohort Study
Participants Gender
Male
Female